Autres langues HBM Healthcare Investments AG

Actions

HBMN

CH0012627250

Gestion des placements et exploitants de fonds

Temps réel estimé Cboe Europe Autres places de cotation 13:57:28 17/07/2026			Varia. 5j.	Varia. 1 janv.
249,50 ^CHF	-1,19%		0,00%	+10,15%

02/07	HBM Healthcare Investments anticipe un bénéfice de 238 millions de francs suisses pour son premier trimestre fiscal	MT
01/07	HBM à nouveau profitable au premier trimestre décalé 2026/27	AW

Autres langues

16/07	Key Figures 15.07.2026
07/07	Fore Biotherapeutics Inc. announced that it has received $110 million in funding from a group of investors
02/07	HBM Healthcare Investments Expects CHF238 Million Profit for Fiscal Q1
01/07	HBM Healthcare kündigt starkes Quartalsergebnis an
01/07	HBM Healthcare Investments mit starker Quartalsperformance – erwarteter Gewinn von CHF 238 Millionen
01/07	HBM Healthcare Investments delivers strong quarterly performance, expects profit of CHF 238 million
01/07	HBM Healthcare Investments AG Provides Earnings Guidance for the Quarter Ended 30 June 2026
01/07	Key Figures 30.06.2026
16/06	Key Figures 15.06.2026
15/06	Shareholders’ Meeting of HBM Healthcare Investments approved all proposals by the Board of Directors
15/06	Generalversammlung der HBM Healthcare Investments stimmt allen Anträgen des Verwaltungsrats zu
11/06	HBM profitiert vom US-Börsengang von Portfoliounternehmen
11/06	HBM Healthcare Investments' Stake Value Jumps in Parabilis Medicines IPO
11/06	HBM Healthcare Investments profitiert vom erfolgreichen Börsengang von Parabilis Medicines
11/06	HBM Healthcare Investments benefits from successful IPO of Parabilis Medicines
10/06	Lycia Therapeutics, Inc. announced that it expects to receive $75 million in funding
01/06	Key Figures 31.05.2026
01/06	HBM Healthcare Investments Completes Sale of Swixx Biopharma Stake
01/06	HBM schliesst Verkauf von Swixx Biopharma-Anteilen ab
01/06	HBM Healthcare Investments gibt den Abschluss der Swixx-Biopharma-Transaktion mit SK Capital und Bain Capital Life Sciences bekannt
01/06	HBM Healthcare Investments Announces Closing of Swixx Biopharma Transaction with SK Capital and Bain Capital Life Sciences
26/05	HBM-Portfoliofirma Curevo an Eli Lilly verkauft
26/05	Eli Lilly to Buy Curevo Vaccine in Up to $1.5 Billion Deal
26/05	Eli Lilly übernimmt HBM-Portfoliounternehmen Curevo für bis zu USD 1.5 Milliarden
26/05	Eli Lilly to Acquire HBM Portfolio Company Curevo for up to USD 1.5 Billion